Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Conserving Surgery, Endoscopic Su...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The center plans to carry out a prospective clinical study of single hole total endoscopic breast conserving surgery for early breast cancer compared with open breast conserving surgery, to provide high-level evidence-based medical evidence for the development of endoscopic breast conserving surgery for early breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: endoscopic breast conserving surgery — Breast endoscopy technology completes complex surgical operations through small incisions, achieving aesthetically pleasing results while ensuring tumor safety.

Primary Outcomes

  • Six months after operation SURVIVAL EFFECTS (From enrollment to the end of 6 months after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2025-06
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ren,Yu
Contact Information
Study Contact:
Zhaoli Nan, bacheior
15114822852
369075227@qq.com
Yu Ren, MD,PhD
13700222161
renyyyyy@126.com
the First Affiliated Hospital of Xi'an Jiaotong University
Interventions
  • Procedure: endoscopic breast conserving surgery — Breast endoscopy technology completes complex surgical operations through small incisions, achieving aesthetically pleasing results while ensuring tumor safety.
Study Locations (1 sites)
the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061 China
Eligibility Criteria
Inclusion Criteria: 1. Breast cancer confirmed by pathology; 2. Tumor \<5 cm, TNM stage 0-II; 3. Single Port Endoscopic or traditional open surgery; (4)20 to 70 years old female patients. Exclusion Criteria: 1. Bilateral breast cancer; 2. Reconstruction after breast conserving surgery ; 3. Basic information is not complete; 4. Breast conserving surgery was converted to modified radical resection or subcutaneous adenoidectomy.
Conditions Hypertension
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Does the m-Health intervention have a positive effect on the health literacy and health promotion behaviors of the study participants?

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Other: Experimental Group — The experimental group participates in the Mobio Health Multimedia Hypertension Promotion Program, which includes a hypertension education manual and a mobile health (m-health) intervention aimed at enhancing participants' health literacy and promoting healthy behaviors. In the first week, participants receive the health-education manual on-site, with face-to-face explanations and guidance on using mobile resources, such as text messaging, provided by the Sub-Investigator. The mobile health intervention transforms the manual's content into six video units, each covering a specific topic, and these videos are continuously pushed over a two-month period. Distributed through LINE@, the official LINE account of the nursing platform, participants can easily access information via the chat menu at the bottom of the screen. This setup improves accessibility, making it convenient for participants to locate and use essential health information directly from the chat window.
  • Other: control group — The control group received one copy of the same health education manual as the experimental group. The sub-Investigator only explained how to use the manual, and afterwards, no face-to-face teaching or m-Health interventions were conducted. After the experiment concluded, the m-Health program used by the experimental group would be provided to the control group.

Primary Outcomes

  • 1.To explore the effectiveness of mobile health(m-health) interventions on the health literacy of study participants. 2.To explore the effectiveness of mobile health(m-health) interventions on the health promotion behaviors of study participants. (1.Total duration for Each Participant: 2 months Intervention Period: From December 2024 to December 2025)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-07
Completion: 2025-12-31
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chimei Medical Center
Principal Investigators:
  • Su.Chiu Hsiao (PRINCIPAL_INVESTIGATOR) - Chi Mei Medical Center,Liouying Director Nursing Department
Contact Information
Study Contact:
Man-Ting Cheng
+886 961062509
hate6699@gmail.com
Man-Ting cheng
+886 961062509
hate6699@gmail.com
Chi Mei Hospital, Liouying
Interventions
  • Other: Experimental Group — The experimental group participates in the Mobio Health Multimedia Hypertension Promotion Program, which includes a hypertension education manual and a mobile health (m-health) intervention aimed at enhancing participants' health literacy and promoting healthy behaviors. In the first week, participants receive the health-education manual on-site, with face-to-face explanations and guidance on using mobile resources, such as text messaging, provided by the Sub-Investigator. The mobile health intervention transforms the manual's content into six video units, each covering a specific topic, and these videos are continuously pushed over a two-month period. Distributed through LINE@, the official LINE account of the nursing platform, participants can easily access information via the chat menu at the bottom of the screen. This setup improves accessibility, making it convenient for participants to locate and use essential health information directly from the chat window.
  • Other: control group — The control group received one copy of the same health education manual as the experimental group. The sub-Investigator only explained how to use the manual, and afterwards, no face-to-face teaching or m-Health interventions were conducted. After the experiment concluded, the m-Health program used by the experimental group would be provided to the control group.
Study Locations (1 sites)
Chi Mei Hospital, Liouying, Tainan, Taiwan 73657 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with hypertension for one year or more (including) and controlled with medication (systolic blood pressure ≥ 130 mmHg and diastolic blood pressure ≥ 80 mmHg). 2. Aware hypertensive patients aged ≥ 45 years with the ability to read and write. 3. Able to take medication independently. 4. Own a smartphone and are able to use it, and are willing to receive text messages (TxtM) or mobile health interventions (m-Health). 5. Agree to participate in the study. Exclusion Criteria: 1. Have cognitive impairments or mental disorders. 2. CCI (Charlson Comorbidity Index) score ≥ 3.

Filipino Family Health Initiative 1.0

NCT06569303
Recruiting
Conditions Depression, Anxiety, Parenting
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test the effectiveness of an online parenting program on Filipino parents living in California. The main aims are to: * Test the effectiveness of the online Incredible Years® model of parent training and its impact on primary outcomes. * Determine the impact of intervention engagement (i.e., higher attendance) on parenting practices and child behavior outcomes. * Describe Intervention delivery and its online implementation in real-world community settings. The study involves two phases: * Phase 1: Participants will receive the Online Incredible Years® School Age Basic \& Advanced Parent Training Program (intervention) and complete parent-reported and child-reported measures at baseline, 3 months and 6 months. * Phase 2: Parenting Group Leaders will each participate in one semi-structured interview to inform the sustainability of the intervention in real world community settings. Researchers will compare 250 Filipino families, half of which will receive the intervention and the other half will receive the American Academy of Pediatrics' Bright Futures handouts (control) and be placed on a 3-month waitlist for the IY parenting program. Both groups will be followed for a minimum of 6 months with follow- up assessments that include parent-report and child report measures.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Incredible Years® School Age Basic Parent Training Program — The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
  • Behavioral: American Academy of Pediatrics, Bright Futures Handouts — Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.

Primary Outcomes

  • Parent Reported Positive Verbal Discipline (Baseline, 3 months, 6 months)
  • Child Reported Depression Symptoms (Baseline, 3 months, 6 months)
  • Child Reported Anxiety Symptoms (Baseline, 3 months, 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2028-03-31
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kaiser Permanente
Collaborators: Children's Hospital Los Angeles, University of Southern California, University of California, San Diego, National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Joyce R Javier, MD MPH MS (PRINCIPAL_INVESTIGATOR) - Kaiser Permanente School of Medicine
Contact Information
Study Contact:
Joyce R Javier, MD MPH MS
626-862-7072
joyce.r.javier@kp.org
Lindsey R Thompson, MS, MPH
lindsey.r.thompson@kp.org
Jasmine Raymundo, MPH
949-385-1427
kpsom-incrediblefamilies@kp.org
Kaiser Permanente Bernard J. Tyson School of Medicine
Interventions
  • Behavioral: Incredible Years® School Age Basic Parent Training Program — The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
  • Behavioral: American Academy of Pediatrics, Bright Futures Handouts — Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
Study Locations (1 sites)
Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101 United States
Eligibility Criteria
Inclusion Criteria: * Parent or legal guardian of at least one child 8-12 years of age * Parent or legal guardian is of Filipino descent * Parent or legal guardian and child are English speaking * Pregnant women or legal guardians may be included if they have a child who meets the inclusion and exclusion criteria Exclusion Criteria: * Family plans to move out of the state of California within the next 6 months * Family has previously participated in the Incredible Years (IY) curriculum * Parent or legal guardian are not fluent in English * Adults unable to consent or children unable to assent * Prisoners Note: All parent participants in the study are 18 years or older. Youth participants are 8-12 years old.
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase PHASE4
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if early combination with two antidiabetic drugs further improves blood glucose control compared to a single drug regimen in adults with short duration of type 2 diabetes. It will also learn about the effect of the combination treatment on body weight, body composition, blood lipids, oxidative stress, inflammation, metabolic control, insulin resistance and insulin secretion from pancreas, together with its safety profile. The main questions it aims to answer are: * Does early combination with two antidiabetic drugs improve blood glucose levels, determined by continuous glucose monitoring system? * Is early combination treatment as safe as treatment with a single antidiabetic drug? * Does early combination treatment reduces the need for rescue therapy? * Does early combination treatment reduces body weight and improves body composition? * Does early combination treatment improves blood lipid parameters, oxidative stress and inflammation? * Does early combination treatment improves metabolic parameters? * Does early combination treatment improves insulin resistance and insulin secretion? Researchers will compare early combination treatment with metformin and either peroral semaglutide or empagliflozin to a single drug regimen with only metformin to see if the combination treatment works to treat type 2 diabetes. Participants will: * Take the combination of two antidiabetic drugs or only metformin for every day for 26 weeks. * Visit the clinic four times during the study duration for checkups and tests. * Carry a continuous glucose monitoring sensor for 14 days prior to study visits.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Oral semaglutide — Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
  • Drug: Empagliflozin 10 mg — Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.

Primary Outcomes

  • Time in Range (TIR) (Period of 14 days prior to last study visit (week 26))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-10-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Centre Ljubljana
Contact Information
Study Contact:
Jaka Sikonja, MD
+38640778882
jaka.sikonja@kclj.si
University Medical Centre Ljubljana, Diabetes Outpatient Clinic
Andrej Janez, MD, PhD
University Medical Centre Ljubljana, Diabetes Outpatient Clinic
Urh Groselj, MD, PhD
University Medical Centre Ljubljana, Diabetes Outpatient Clinic
Interventions
  • Drug: Oral semaglutide — Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
  • Drug: Empagliflozin 10 mg — Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
Study Locations (1 sites)
University Medical Centre Ljubljana, Diabetes Outpatient Clinic, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes for up to 2 years (prior to randomization); * Aged between 18 and 70 years, both sexes, of any race or ethnicity; * HbA1c ≤8.0% at randomization; * Baseline treatment with metformin at a steady daily dose of ≥1500 mg; * Signed informed consent to participate in the study. Exclusion Criteria: * Treatment at any time in the past with SGLT2i, GLP-1RA, or DPP-4 inhibitors; * Insulin treatment for longer than 2 weeks in the past; * Body Mass Index below 22 kg/m2 or BMI above 40 kg/m2; * Chronic kidney disease stages 3-5 (eGFR below 60 ml/min or the presence of albuminuria (urine albumin-to-creatinine ratio above 34 g/mmol); * Known cardiovascular disease (angina pectoris, history of myocardial infarction, ischemic heart disease, heart failure, known carotid atherosclerosis, objectively proven peripheral arterial disease, or other known atherosclerotic disease at other locations); * Moderate or severe liver disease (Child-Pugh stage B or C); * Personal history of pancreatitis; * Advanced heart failure (NYHA III-IV); * Retinopathy or maculopathy or their active treatment; * Pregnancy, expected pregnancy, or breastfeeding; * Presence of active malignancy or personal history of malignancy within 5 years of study enrollment; * Personal history of thyroid cancer; personal or family history of multiple endocrine neoplasia type 2 or family history of medullary thyroid carcinoma; * Chronic inflammatory bowel disease; * History of bariatric surgery or other gastrointestinal surgery that could affect drug or nutrient absorption; * Frequent or severe urinary tract infections; * Presence of a urinary catheter; * Troublesome and recurrent genital fungal infections; * Personal history of ketoacidosis; * Symptomatic hypotension or predisposition to hypovolemia; * History of organ transplantation; * Allergy to any component in the semaglutide or empagliflozin oral tablet; * Any medical or social circumstance that may limit participation in the study (e.g., inability to attend regular study visits); * Any other condition that, in the opinion of the principal and responsible investigators, may affect the safety or efficacy of the treatment.
Conditions Hypertension, Uncontrolled, Hypertension...
Phase PHASE4
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Our previous study (Huang HC, Pan HY, Wang TD, Circ Cardiovasc Interv 2023;16:e012779) demonstrated that when renal artery stimulation continues to trigger systolic blood pressure increases (\>=20 mmHg increase compared to baseline) after the initial procedure, patients show poor blood pressure reduction 6 months following renal denervation. Based on this finding, we designed a proof-of-concept trial comparing two approaches: a guided strategy versus conventional renal denervation. In the guided strategy, we perform additional ablations of main and/or branch renal arteries if immediate post-procedure stimulation still elevates systolic blood pressure (\>=20 mmHg increase compared to baseline). The conventional approach involves no repeat procedures. This trial aims to determine whether the guided strategy leads to better clinical outcomes, measured by 6-month ambulatory blood pressure changes, and to establish the value of using intraprocedural feedback to assess and guide renal denervation treatment.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Radiofrequency ablation alone, re-denervation to main and/or branch renal artery — Re-denervation according to the site where renal artery stimulation can induce systolic blood pressure rise of \>= 20 mmHg. Main renal artery denervation if proximal main renal artery stimulation positive, while branch renal artery denervation if distal main renal artery stimulation positive.
  • Procedure: Radiofrequency ablation alone, no further renal denervation — No further renal denervation after standard renal denervation even renal artery stimulation-induced systolic blood pressure rise \>= 20 mmHg

Primary Outcomes

  • 24-hour systolic blood pressure reduction (compared to baseline) (6 months following the index renal denervation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-10-14
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Collaborators: Smart Health Technology Research and Development Center, National Taiwan University, Medtronic
Principal Investigators:
  • Tzung-Dau Wang, MD, PhD (PRINCIPAL_INVESTIGATOR) - National Taiwan University Hospital
Contact Information
Study Contact:
Tzung-Dau Wang, MD, PhD
886-972651070
tdwang@ntu.edu.tw
Ya-Chun Chen, BS
886-2-23123456
yachun0411@gmai.com
Tzung-Dau Wang, MD, PhD
886-972651070
tdwang@ntu.edu.tw
National Taiwan University Hospital
Interventions
  • Device: Radiofrequency ablation alone, re-denervation to main and/or branch renal artery — Re-denervation according to the site where renal artery stimulation can induce systolic blood pressure rise of \>= 20 mmHg. Main renal artery denervation if proximal main renal artery stimulation positive, while branch renal artery denervation if distal main renal artery stimulation positive.
  • Procedure: Radiofrequency ablation alone, no further renal denervation — No further renal denervation after standard renal denervation even renal artery stimulation-induced systolic blood pressure rise \>= 20 mmHg
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, 100225 Taiwan
Eligibility Criteria
Inclusion Criteria: * Patients with hypertension and are willing to undergo renal denervation. * Patients are treated with antihypertensive medications, or with an office systolic blood pressure (SBP) \>140 mm Hg or diastolic blood pressure (DBP) \>90 mm Hg, and 24-hour SBP of \>130 mmHg or DBP \>80 mm Hg, irrespective of antihypertensive treatment. Exclusion Criteria: * An unsuitable renal artery anatomy for renal denervation, assessed by computed tomographic angiography (main renal artery lumen diameter \<3 mm or a total length \<20 mm). * Secondary hypertension, including hyperaldosteronism, pheochromocytoma, and renal artery stenosis (\>50% stenosis in one or both arteries).
Conditions Type 2 Diabetes
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, double-blind, placebo-controlled clinical trial. The objective of this trial is to determine whether Lactobacillus paracasei LC19 supplementation has a positive effect on glucose lowering in patients with type 2 diabetes (T2D).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Lactobacillus paracasei LC19 supplementation — Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
  • Dietary Supplement: Placebo probiotic milk powder — Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).

Primary Outcomes

  • HbA1c change (From enrollment to the end of treatment at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-12
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Chao Yang Hospital
Principal Investigators:
  • Guang Wang, MD (PRINCIPAL_INVESTIGATOR) - Beijing Chao Yang Hospital
Contact Information
Study Contact:
Jia Liu, MD
010-85231710
liujia0116@126.com
Xiaoyu Ding, MD
010-85231711
dxycy0828@163.com
Jia Liu, MD
010-8523161710
dxycy0828@163.com
Beijing Chao-yang Hospital, Capital Medical University
Interventions
  • Dietary Supplement: Lactobacillus paracasei LC19 supplementation — Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
  • Dietary Supplement: Placebo probiotic milk powder — Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
Study Locations (1 sites)
Beijing Chao-yang Hospital, Capital Medical University, Beijing, Beijing Municipality 100020 China
Eligibility Criteria
Inclusion Criteria: * Age 18-65 years, both genders eligible * Drug-naive patients with newly diagnosed type 2 diabetes * Subjects with screening HbA1c ≥ 7.0% and ≤ 9.0% * Subjects understand the nature, significance, potential benefits, inconvenience, and risks and procedure of the study, and voluntarily sign the informed consent form Exclusion Criteria: * Other types of diabetes except T2D: type 1 diabetes (including adult latent autoimmune diabetes), special type diabetes, or secondary diabetes (such as acromegaly or Cushing\&amp;amp;amp;#39;s syndrome, etc.) * Subjects with acute diabetic complications such as diabetic ketoacidosis or diabetic hyperosmolar coma in the past 6 months * Subjects with history of hypoglycemia in the past 6 months * Subjects with history of New York Heart Association class (NYHA) grade of heart function ≥ III or serious cardiovascular diseases (myocardial infarction, or with the history of cardiac interventional therapy or stent implantation, valve disease or valve repair, unstable angina, transient ischemic attack or stroke) within 6 months before the screening period * Subjects with history of chronic active hepatitis and/or severe liver dysfunction, renal dysfunction, and thyroid dysfunction * Subjects with a medical history of malignant tumor * Subjects with history of gastrointestinal diseases that affect food digestion and absorption (such as severe diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, active gastrointestinal ulcers, acute cholecystitis, etc.) or with a history of intestinal resection or other gastrointestinal surgery (such as cholecystectomy) within one year before the screening period * Subjects with history of surgery, or severe trauma in the past 6 months, or planning to undergo surgery during the study period * Subjects suffering from severe infections, severe anemia, or neutropenia * Subjects pregnant or in lactation, or those planning to become pregnant or impregnate during or within 3 months after the study period * Subjects with history of receiving immunosuppressants, steroids, anti diarrheal drugs, antibiotics, lipid-lowering drugs, or other gastrointestinal motility medications within the past 3 months; * Subjects using other medications that can affect blood glucose in the past 3 months * Subjects with consumption of other probiotic or prebiotic products in the past 3 months before secreening * Subjects with lactose intolerance, known or suspected allergy to probiotics used in experiments, history of drug allergies or allergic diseases * Subjects with weight fluctuations ≥ 5kg in the past 3 months or planning to take medication to control weight during the study period * Subjects with history of mental illness or epilepsy, or taking antidepressant medications * Subjects with history of alcohol abuse (for men, alcohol consumption exceeding 40 grams per day and for women, exceeding 20 grams per day) * Subjects have participated in any other clinical study in the past 3 months
Conditions Glaucoma, Ocular Hypertension
Phase NA
Enrollment 1800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if implementation of an eye screening program at Federally Qualified Health Center (FQHC) clinics provides results that participants may have glaucoma, and/or other eye conditions (diabetic retinopathy, cataract, visual acuity impairment). The glaucoma screening will incorporate use of an artificial intelligence (AI)-assisted screening tool. This project is called AI-RONA. The main questions it aims to answer are: * How does this eye screening program compare to the rate of glaucoma and other eye conditions detected at other FQHC clinics where the screening program has not been implemented? * Do particpants who screen positive for these conditions adhere to the physician's recommendation for a follow-up examination by an optometrist or ophthalmologist? * Are referral rates for a follow-up comprehensive eye exam by an optometrist or ophthalmologist similar to those implemented by an ophthalmologist using telemedicine (that is, using the results of the screening to make a diagnosis remotely)? * What is the cost-effectiveness of the AI-assisted screening program in diagnosing glaucoma as compared to a physician-guided program? * Are participants completing the screening satisfied with it? * Are physicians at the FQHC clinics administering the screening satisfied with it? Participants will: * Undergo an ocular screening whose goal is to detect glaucoma, diabetic retinopathy, cataract, and/or impairment in visual acuity. If the screening indicates that participants may have these conditions, participants will be referred for a comprehensive eye examination by an optometrist or ophthalmologist. * Following the screening, participants and physicians will complete a survey on their satisfaction with the program.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment. — Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.

Primary Outcomes

  • Rate of participants where the glaucoma screening protocol leads to a screening diagnosis of glaucoma (up to 2-3 days)
  • Rate of participants who decide to attend the follow up exam by optometrist or ophthalmologist (up to 4 months)
  • Rate of participants where the screening protocol leads to a screening diagnosis of cataract, diabetic retinopathy, or visual acuity impairment (up to 2-3 days)
  • Compare cost of screening program in FQHC to the cost of an ophthalmologist or optometrist guided assessment (up to 4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-22
Completion: 2029-09-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: Centers for Disease Control and Prevention, University of California, San Diego
Principal Investigators:
  • Cynthia Owsley, PhD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Cynthia Owsley, PhD
205-325-8635
cynthiaowsley@uabmc.edu
Dawn Matthies, PhD
205-325-8631
dmatthies@uabmc.edu
Dawn Matthies, PhD
205-325-8631
dmatthies@uabmc.edu
Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham
Interventions
  • Other: Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment. — Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.
Study Locations (1 sites)
Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, Alabama 35294-0009 United States
Eligibility Criteria
Inclusion Criteria: * African American or Hispanic persons ≥ 40 years old * Non-Hispanic white persons ≥ 50 years old * Anyone ≥ 18 years old with diabetes type 1 or type 2 * Anyone ≥ 18 years old who already has a glaucoma associated disease * Anyone ≥ 18 years old with a family history of glaucoma Exclusion Criteria: * Declines to sign written informed consent * Cannot communicate in English
Conditions Psychosis
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to investigate the role of the immune system in psychotic symptoms and their response to treatment. The investigators will collect blood and cerebrospinal fluid samples from participants with psychosis symptoms who are about to start or change to a new regular antipsychotic treatment as well as a control group for comparison. Participants will be assessed at two main timepoints, at visit 1 (Week 0) and at visit 2 (4 +/-2 weeks). For participants with psychosis symptoms visit 1 will take place at the start or change of antipsychotic medication. The studies goal is to identify biomarkers that can aid in diagnosis, prognosis, treatment selection, and tracking treatment response. The investigators aim to recruit participants from the following groups: 1. Individuals with psychosis symptoms presenting to acute or outpatient services who are due to be started on or change to a new regular antipsychotic medication. 2. Age- and sex-matched control participants without neuropsychiatric disease. Findings could potentially impact the treatment of psychotic illnesses by offering mechanistic insights into targeted immune-based interventions for these disorders through high-resolution immunophenotyping techniques alongside targeted immunological assays. Ultimately, the research aims to contribute valuable resources for future studies exploring the connection between immune processes and neuropsychiatric conditions.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Peripheral Immune Phenotype (4 +/-2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-06
Completion: 2031-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King's College London
Collaborators: South London and Maudsley NHS Foundation Trust, University of Oxford, McPin Foundation, Francis Crick Institute
Contact Information
Study Contact:
Thomas Pollak (Chief Investigator), PhD
+442078485288
IMATStudy@kcl.ac.uk
Amy Aldridge (Project Manager)
+442078485288
IMATStudy@kcl.ac.uk
Thomas Pollak, PhD
+442078485288
IMATStudy@kcl.ac.uk
South London and Maudsley NHS Foundation Trust
Interventions
N/A
Study Locations (1 sites)
South London and Maudsley NHS Foundation Trust, London, United Kingdom SE5 8AB United Kingdom
Eligibility Criteria
Inclusion Criteria Participants with psychosis symptoms: * Age 18-65 * Currently experiencing psychosis symptoms warranting treatment by secondary care mental health services, as confirmed by a psychiatrist involved in their treatment. * Psychosis symptoms likely to be attributable to a disorder represented by ICD codes F20-F39, in the opinion of the treating clinical team. * Due to start or change to a new regular antipsychotic medication. (Participants who are initiating antipsychotic treatment for the first time, transitioning to a different antipsychotic medication, or resuming a formerly prescribed antipsychotic medication that was discontinued for a minimum of two weeks may be recruited.) Control Participants * Age 18-65 * No active autoimmune disorder. * No history of psychosis symptoms. Exclusion Criteria Participants with psychosis symptoms: * Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance. * Currently taking or having taken in the last four weeks any medication known to grossly affect the production or function of immune cells (e.g. corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, rituximab or other monoclonal antibody therapies). * Inability to have blood tests. Control participants: * Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance. * Currently taking or having taken in the last four weeks any medication known to grossly affect the production or function of immune cells (e.g. corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, rituximab or other monoclonal antibody therapies). * Inability to have blood tests. Optional lumbar puncture only: * Significant lower spinal deformity (such as spina bifida), injury (such as stenosis) or previous lower spinal surgery. * Antiplatelet or anticoagulant therapy within the 14 days prior to Lumbar Puncture procedure. * Known or suspected clotting disorder. * Clinically significant abnormality in full blood count. * Known or suspected raised intracranial pressure, assessed by study clinician. * Known or suspected allergy to local anaesthetic agent or an ingredient of the anaesthetic solution. * History of chronic or recurrent headaches, in the opinion of the investigator.
Conditions Depression
Phase PHASE1, PHASE2
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: Ketamine-assisted psychotherapy — Ketamine-assisted psychotherapy delivered in a group format

Primary Outcomes

  • Evaluate feasibility of a culturally adapted group-based ketamine intervention for Spanish- speaking adults with depression in a community setting (1 week post-intervention)
  • To assess the safety of a ketamine-assisted group psychotherapy intervention for Spanish-speaking participants with depression in a community setting. (1 week post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-07-23
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Juliana Zambrano, MD, MPH
Principal Investigators:
  • Juliana Zambrano, MD (STUDY_DIRECTOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Juliana Zambrano, MD
617-726-2000
JZAMBRANO2@mgh.harvard.edu
Juliana zambrano, MD, MPH
6177262000
jzambrano2@mgh.harvard.edu
Massachusetts General Hospital, Chelsea
Interventions
  • Drug: Ketamine-assisted psychotherapy — Ketamine-assisted psychotherapy delivered in a group format
Study Locations (1 sites)
Massachusetts General Hospital, Chelsea, Chelsea, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1\. Self-identifying Latinx, Spanish-speaking 2. Adults 18-64 years 3. Meet DSM-5 criteria for major depressive disorder as evaluated by study clinician 4. Montgomery-Asberg depression scale (MADRS) score of 20 or above at baseline 4. Participants must have an MGB psychiatrist and primary care provider. Exclusion Criteria: 1. History of primary psychotic disorder, by history 2. History Bipolar I disorder, by history 3. Unstable complex PTSD, as assessed by study clinician 4. History of dissociative identity disorder 5. History of neurocognitive disorder 6. History of severe and/or recent substance use disorder, by history and as assessed by study clinician after clinical evaluation and interview 7. Uncontrolled hypertension, tachycardia, or unstable cardiopulmonary disease, by history a. Blood pressure on initial screen must be \<140/90 mmHg. 8. History of aortic dissection 9. History of myocardial infarction 10. History of aneurysm 11. History of hepatic impairment. 12. History of epilepsy 13. History of prior hypersensitivity to ketamine 14. Body Mass Index greater than 35 15. Body Mass Index less than 18.5 16. Are pregnant, breastfeeding, or planning to become pregnant within 12 weeks of treatment completion 17. Enrolled in other clinical trial for the treatment of depression or other behavioral health diagnosis 18. Inability to provide consent.
Conditions Breast Cancer, Esophageal Cancer, Kidney...
Phase PHASE1
Enrollment 11
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Brodalumab — Brodalumab 210 mg subcutaneous injection
  • Radiation: CT scan — CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment

Primary Outcomes

  • Number of Adverse Events (Up to 36 weeks)
  • Percentage of primary Immune-Related Adverse Event (irAE) severity decreased (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-03-11
Completion: 2027-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 11 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brian Henick, MD
Collaborators: Bausch Health Americas, Inc.
Principal Investigators:
  • Brian Henick, MD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Research Nurse Navigator
212-342-5162
cancerclinicaltrials@cumc.columbia.edu
Brian Henick, MD
212-305-5098
bh2682@cumc.columbia.edu
Columbia University Irving Medical Center
Interventions
  • Drug: Brodalumab — Brodalumab 210 mg subcutaneous injection
  • Radiation: CT scan — CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment
Study Locations (1 sites)
Columbia University Irving Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Ability to provide written informed consent by subject or guardian * Individuals \>18 years of age * Diagnosis of an irAE clinically suspected to be IL-17 mediated * Intent-to-treat or prior treatment with systemic steroids for irAE management * Histology-proven primary advanced or metastatic solid organ malignancy treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll. * Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\< 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation. * Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test. * Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab. Exclusion Criteria: * Estimated creatinine clearance \< 40 mg/min * Active suicidal ideation or severe depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score \> 20 * History of prior suicide attempts * PHQ-9 score greater \>5 and \< 20 without an established mental health provider who verifies stability in their depression * Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV) * In the opinion of the investigator, the patient requires additional immunosuppressive treatment (other than corticosteroids and brodalumab) * Known hypersensitivity or contraindication to brodalumab, corticosteroids or any components of brodalumab * Prior treatment with brodalumab * Pregnancy, breastfeeding, or use of a nonreliable method of contraception * For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years postmenopausal, with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range). * Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method. * Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll * Chronic or current severe infection requiring IV therapy * Evidence of active hepatitis B, C, or tuberculosis. * History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated * History of or active Crohn's disease. * Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first investigational product dose * Any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject. * Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report * Other known clinically significant active medical conditions, such as: * Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D) * Aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal or greater than 3 times the upper limit of normal in patients with liver metastases measured on at least two separate occasions * Direct bilirubin greater than or equal to 1.5 mg/dL in patients with or without liver metastases * Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \<2000/mm3, absolute neutrophil count \<1500/ mm3, thrombocytopenia (platelet count) \<50,000/mm3, hemoglobin \< 8.0 g/dL * Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE * Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit * Previous diagnosis of an autoimmune disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration * Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation * Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab
Conditions Locally Advanced Breast Cancer
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

For newly diagnosed ISLNM breast cancer, on the basis of effective treatment of the new auxiliary system, the optimal local treatment of the supraclavicular region remains controversial. Although guidelines such as NCCN recommend simple clavicular radiation therapy, there are studies suggesting that supraclavicular lymph node dissection can improve prognosis, and many hospitals in China are still accustomed to performing supraclavicular lymph node dissection. Therefore, ipsilateral supraclavicular lymph node dissection is the first time to diagnose ipsilateral supraclavicular lymph node metastasis of breast cancer. The effectiveness and safety of (stage IIIc) treatment still require prospective research to confirm.This project is a prospective, multicenter, non-interference real world study. In the real world study, the investigators evaluated the efficacy and safety of ipsilateral supraclavicular lymph node dissection in the treatment of initially diagnosed ipsilateral supraclavicular lymph node metastasis breast cancer patients.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Procedure: Subclavian lymph node dissection+radiotherapy — The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.
  • Procedure: Simple clavicular region radiotherapy — If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.

Primary Outcomes

  • Intraclavicular recurrence free survival in group A patients (5th year after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-04
Completion: 2027-04-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: Not specified
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Principal Investigators:
  • xiuchun Chen (STUDY_CHAIR) - Henan Cancer Hospital
Contact Information
Study Contact:
xiuchun Chen
0371-65587405
zlyychenxiuchun3921@zzu.edu.cn
Minhao Lv
0371-65587405
zlyylvminhao2789@zzu.edu.cn
Minhao Lv
0371-65587405
zlyylvminhao2789@zzu.edu.cn
Henan Cancer Hospital
Interventions
  • Procedure: Subclavian lymph node dissection+radiotherapy — The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.
  • Procedure: Simple clavicular region radiotherapy — If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.
Study Locations (1 sites)
Henan Cancer Hospital, Zhengzhou, Henan 450000 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged ≤ 80 years old. 2. ECOG score 0-1 points; 3. Breast cancer meets the following criteria: histologically diagnosed as invasive breast cancer, known ER, PR, HER2, KI67 status, pathologically diagnosed as ipsilateral supraclavicular lymph node metastasis (both cytology and histopathology); 4. Estimated patient survival time exceeding three months; 5. No obvious contraindications for surgery or radiotherapy; 6. The researcher judged that they were able to comply with the research protocol. 7. Those who participate in other clinical trials (including intervention or non intervention studies) at the same time and are judged by the researchers not to affect the research protocol can be enrolled normally. 8. Voluntarily participate in this study and sign an informed consent form. Exclusion Criteria: 1. Stage IV (metastatic) breast cancer; 2. Bilateral breast cancer; 3. Received radiotherapy and surgical treatment (excluding local puncture) for ipsilateral supraclavicular metastatic lymph nodes before enrollment; 4. History of breast cancer or other malignant tumors, but excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma; 5. Individuals with severe primary diseases such as cardiovascular, cerebrovascular, liver, and kidney that are difficult to tolerate surgery or radiation therapy; 6. Having a history of immunodeficiency, including HIV testing positive, or having other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation; 7. Suffering from severe comorbidities or other comorbidities that may interfere with the planned treatment, or any other circumstances in which the researcher deems the patient unsuitable to participate in this study.
Conditions Breast Neoplasm
Phase Not Applicable
Enrollment 330
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

EXoPERT has developed a liquid biopsy-based in vitro diagnostic medical device that can diagnose cancer through blood. The in vitro diagnostic medical device for this clinical performance trial is a test device that applies a technology that measures Raman spectroscopic signals of extracellular vesicles in the blood and classifies high-risk and low-risk patients for breast cancer through artificial intelligence analysis. The test device used in this clinical performance trial is expected to assist in the differential diagnosis of high-risk and low-risk breast cancer patients by developing a software algorithm for an in vitro diagnostic medical device for auxiliary diagnosis that classifies high-risk and low-risk breast cancer patients and confirming the clinical efficacy and safety of the device through this clinical performance trial.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: ExoPred — Performing in vitro diagnostics with devices developed by EXoPERT

Primary Outcomes

  • Sensitivity (through study completion, an average of 1 year)
  • Specificity (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-16
Completion: 2026-12-31
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 330 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: EXoPERT
Contact Information
Study Contact:
Jongwon Choi
+82-10-3931-2941
necain1003@exopert.com
808-586-2979
Univercity of Hawaii Cancer Center
Dongwon You
+82-10-3062-8833
dwyou@exopert.com
Korea University Anam Hospital
Interventions
  • Diagnostic Test: ExoPred — Performing in vitro diagnostics with devices developed by EXoPERT
Study Locations (3 sites)
Univercity of Hawaii Cancer Center, Honolulu, Hawaii 96813 United States
Korea University Anam Hospital, Seoul, South Korea
Korea University Guro Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria(Breast malignant nodule group) 1. Korean nationality 2. Voluntary written consent to participate in this clinical performance trial study 3. Confirmed breast cancer through imaging/pathologic diagnostic tests 4. Those who have been diagnosed with breast cancer at a stage prior to treatment and surgery, and who agree to participate in this study and are able to provide blood samples. 5. Those whose lesions have been confirmed by conventional examination (breast ultrasound or mammography) and who fall into BI-RADS categories 4,5,6 and have undergone biopsy or are scheduled to undergo biopsy within 2 weeks. 6. Those who meet the following demographic conditions A. Adult female, 40 years of age or older 7. Those who can provide the following clinical information A. Age and biological sex B. Whether or not they have dense breasts C. Occupational information D. Pathological tumor size, Clinical tumor size, Pathological TNM staging, Clinical TNM staging, tumor location, breast cancer histology findings (breast cancer subtype) E. Family history and past history of cancer F. Breast-related diseases G. Chronic disease history Inclusion Criteria(Breast benign nodule group) 1. Korean nationality 2. Voluntary written consent to participate in this clinical performance trial study 3. Diagnosed with breast nodules through imaging/pathologic diagnostic tests 4. Those who have been diagnosed with breast nodules and have agreed to participate in this study and are able to provide blood samples at a stage prior to treatment and surgery. 5. Those whose lesions have been confirmed by conventional examination (breast ultrasound or mammography) and fall into BI-RADS categories 4,5,6 and have undergone biopsy or are scheduled for biopsy within 2 weeks 6. Those who meet the following demographic conditions A. Adult female, 40 years of age or older 7. Those who can provide the following clinical information A. Age and biological sex B. Whether or not they have dense breasts C. Occupational information D. Diagnosis, nodule size, and number of nodules E. Family history and past history of cancer F. Breast-related diseases G. Chronic disease history Exclusion Criteria: 1. Those who have been diagnosed with cancer (malignant tumor) of any type within 5 years of the date of consent and have undergone appropriate chemotherapy/radiation treatment or surgery. 2. Those who are confirmed to have developed breast cancer due to metastasis from malignant tumors other than breast cancer 3. Pregnant women 4. Participation in a drug-related clinical trial within 3 months of the date of the informed consent form